Business Context and Reporting Period
Company: Teleflex Incorporated (TFX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Reporting Period: Year ended December 31, 2025 (Results announced via press release dated February 26, 2026)
This filing announces the Company's financial results for the fiscal year 2025 and details a new multi-year restructuring plan approved by the Board of Directors on February 23, 2026, in connection with ongoing strategic divestitures.
Key Financial Metrics and Restructuring Estimates
Financial Results: The filing references a press release (Exhibit 99.1) containing GAAP and non-GAAP results for the year ended December 31, 2025. Specific revenue, profit, cash flow, and margin figures are not provided in the text of this 8-K; they are contained in the referenced exhibits.
Restructuring Plan Estimates (Strategic Divestitures):
| Expense Category | Estimated Cost (Millions) |
|---|---|
| Restructuring Charges (Primarily employee termination benefits) | $15 - $18 |
| Restructuring Related Charges (Lease termination, retention incentives) | $16 - $19 |
| Total Estimated Charges | $31 - $37 |
Cash Impact: Substantially all charges are expected to result in future cash outlays, with $15.0 million to $19.0 million expected in 2026.
Expected Savings: Annual pre-tax savings of $48 million to $52 million once fully implemented, with partial realization expected in 2026.
Material Changes and Strategic Actions
- Strategic Divestitures: The Company is proceeding with agreements to divest its Acute Care, Interventional Urology, and OEM businesses. These businesses are being reclassified as discontinued operations in supplemental financial information.
- Restructuring Plan: A new plan was approved to align the global organizational structure and supply chain for remaining businesses. Actions include workforce reductions and capital asset rationalization, expected to be substantially completed by mid-2028.
- Italian Payback Reserve: The Company increased reserves related to legislation requiring payments to the Italian government if medical device expenditures exceed regional ceilings. This adjustment impacts revenue recognition and is excluded from non-GAAP measures.
- Discontinued Products: Approximately $14 million of products were discontinued in 2025 due to strategic realignment.
Guidance, Outlook, and Non-GAAP Measures
Non-GAAP Adjustments: Management utilizes several non-GAAP measures to assess performance, excluding items deemed non-recurring or not indicative of core trends. Key adjustments include:
- Adjusted Revenue: Excludes the impact of increased reserves for prior years related to the Italian payback measure.
- Pro Forma Adjusted Revenue: Excludes the Italian payback reserve, discontinued products ($14 million), and includes revenues from the Vascular Intervention business acquired from BIOTRONIK SE & Co. KG (for the six months ended June 29, 2025).
- Adjusted Diluted EPS: Excludes restructuring charges, impairment charges, acquisition/divestiture costs, separation costs, Italian payback impacts, pension termination charges, EU Medical Device Regulation expenditures, intangible amortization, ERP implementation costs, and tax adjustments.
Outlook: The Company expects to begin realizing a portion of the $48 million to $52 million in annual pre-tax savings from the restructuring plan in 2026.
Investor Verification Checklist
- Verify GAAP Results: Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the year ended December 31, 2025, as they are not listed in this summary text.
- Review Non-GAAP Reconciliations: Examine Exhibit 99.2 (Slide Presentation) for detailed reconciliations between GAAP and non-GAAP measures, specifically regarding the Italian payback reserve and discontinued operations.
- Assess Divestiture Timeline: Confirm the status of the Acute Care, Interventional Urology, and OEM divestitures and the impact on future revenue streams.
- Monitor Restructuring Execution: Track the recognition of the estimated $31 million to $37 million in restructuring charges and the realization of projected cost savings throughout 2026 and 2027.
- Italian Regulatory Risk: Evaluate the potential for future adjustments to the Italian payback reserve based on regional expenditure ceilings and court rulings.